According to a new RAND Corporation study.

This RAND study evaluated the CHOICE program, which is presented during five 30-minute classes in a non-confrontational and non-judgmental manner. This program dispels myths about the prevalence of alcohol use, problems unrealistic beliefs about compound use, presents tips on resisting pressure to make use of substances and stresses the advantages of ceasing or lowering substance use. To date, just three voluntary after-school applications concentrating on substance use have already been evaluated specifically, and CHOICE is the only system for middle school youth. The Prevention Science article presents outcomes from the evaluation of preference through a cluster-randomized managed trial in 16 middle institutions in Southern California. The scholarly study focused on alcohol use, which is the most regularly used element in this age group.The considerable research follows up on earlier work by Illes and colleagues, published in the July 2003 problem of Radiology. That article called attention to the lack of medical profession suggestions for appropriate scanning, while documenting the rapid growth of the direct-to-consumer scanning business. It identified 88 such imaging centers nationwide, and within an interview this past year at the right time of publication, Illes noted that since the extensive research have been completed, some centers had closed their doors but 48 more centers got opened. Furthermore to Illes, the authors of the most recent paper are Dylan Kann, in Stanford’s Plan in Human Biology; Kim Phillip and Karetsky Letourneau at the Center for Biomedical Ethics; Thomas Raffin, MD, professor of medicine, emeritus, and co-director of the Center for Biomedical Ethics; Barbara Koenig, MD, associate professor of neurology and neurological sciences and a faculty member at the Center for Biomedical Ethics; and Scott Atlas, MD, professor of radiology and senior fellow, by courtesy, at the Hoover Institution.

A New Computer-Modelling Tool to boost Psoriasis Administration and Treatment Outcomes At the 17th EADV Conference in Paris, LEO Pharma has unveiled a new weapon in its long-running campaign to improve psoriasis administration and treatment outcomes.